-1.87%
4.65%
-1.75%
8.10%
48.49%
-49.06%
176.14%
AI Spotlight on BCRX
Company Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines.The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.
The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd.BioCryst Pharmaceuticals, Inc.was founded in 1986 and is headquartered in Durham, North Carolina.
Market Data
| Last Price | 7.87 |
| Change Percentage | -1.87% |
| Open | 8.08 |
| Previous Close | 8.02 |
| Market Cap ( Millions) | 1630 |
| Volume | 2168910 |
| Year High | 8.88 |
| Year Low | 4.03 |
| M A 50 | 7.57 |
| M A 200 | 7.08 |
Financial Ratios
| FCF Yield | -3.50% |
| Dividend Yield | 0.00% |
| ROE | 26.40% |
| Debt / Equity | -172.68% |
| Net Debt / EBIDTA | -2582.19% |
| Price To Book | -3.48 |
| Price Earnings Ratio | -13.15 |
| Price To FCF | -28.53 |
| Price To sales | 3.95 |
| EV / EBITDA | -84.92 |
News
- Jan -10 - BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
- Jan -07 - BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference
- Jan -06 - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dec -09 - BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy
- Dec -04 - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nov -18 - BioCryst Launches ORLADEYO® (berotralstat) in Ireland
- Nov -06 - BioCryst to Present at Upcoming Investor Conferences
- Nov -05 - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nov -04 - BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript
- Nov -04 - BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
- Oct -23 - How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5%
- Oct -21 - BioCryst to Report Third Quarter 2024 Financial Results on November 4
- Oct -14 - BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)
- Oct -07 - BioCryst (BCRX) Upgraded to Buy: Here's Why
- Oct -03 - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Oct -02 - BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
- Sep -30 - U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile
- Sep -17 - BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
- Sep -06 - BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
- Sep -04 - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Oral Small Molecule and Protein Therapeutics
Expected Growth : 9.27 %
What the company do ?
Oral Small Molecule and Protein Therapeutics from BioCryst Pharmaceuticals, Inc. are innovative treatments for rare diseases, including hereditary angioedema and complement-mediated diseases.
Why we expect these perspectives ?
BioCryst Pharmaceuticals' Oral Small Molecule and Protein Therapeutics segment growth is driven by increasing demand for convenient, orally administered treatments, advancements in protein therapeutics, and the company's strong pipeline of novel compounds. Additionally, growing prevalence of diseases such as hereditary angioedema and increasing adoption of oral therapies over injectables contribute to the 9.27% growth.
Biocryst Pharmaceuticals, Inc. Products
| Product Range | What is it ? |
|---|---|
| Rapivab | Rapivab is an antiviral medication used to treat and prevent influenza (flu) in adults and children. |
| BCX9930 | BCX9930 is an oral, small molecule factor D inhibitor being developed for the treatment of complement-mediated diseases. |
| BCX9250 | BCX9250 is an oral, small molecule inhibitor of plasma kallikrein being developed for the treatment of hereditary angioedema (HAE). |
| BCX7353 | BCX7353 is an oral, small molecule inhibitor of plasma kallikrein being developed for the prevention of hereditary angioedema (HAE) attacks. |
BioCryst Pharmaceuticals, Inc.'s Porter Forces
Threat Of Substitutes
BioCryst Pharmaceuticals, Inc. operates in a highly competitive industry, but the threat of substitutes is mitigated by the company's focus on developing novel oral serine protease inhibitors for the treatment of hereditary angioedema.
Bargaining Power Of Customers
BioCryst Pharmaceuticals, Inc. has a diverse customer base, including pharmaceutical companies and research institutions, which reduces the bargaining power of individual customers.
Bargaining Power Of Suppliers
BioCryst Pharmaceuticals, Inc. relies on a limited number of suppliers for raw materials and services, which gives them some bargaining power, but the company's strong relationships with suppliers mitigate this risk.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services, posing a significant threat to BioCryst Pharmaceuticals, Inc.'s market share.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players and new entrants vying for market share, leading to a high intensity of rivalry that BioCryst Pharmaceuticals, Inc. must navigate.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 219.26% |
| Debt Cost | 12.74% |
| Equity Weight | -119.26% |
| Equity Cost | 13.75% |
| WACC | 11.53% |
| Leverage | -183.85% |
BioCryst Pharmaceuticals, Inc. : Quality Control
BioCryst Pharmaceuticals, Inc. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OCUL | Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company … |
| LPCN | Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral … |
| EYPT | EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, … |
| PSTX | Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) … |
| ABUS | Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ocular Therapeutix
A-Score
1-Year Total Return ->
🥈
Arbutus Biopharma
A-Score
1-Year Total Return ->
🥉
Lipocine
A-Score
1-Year Total Return ->
4
BioCryst Pharmaceuticals
A-Score
1-Year Total Return ->
5
Poseida Therapeutics
A-Score
1-Year Total Return ->
6
